0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Biosimilar"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,450USDGBP
The Biosimilars Landscape in Japan: 2009-2020 Study - Product Thumbnail Image

The Biosimilars Landscape in Japan: 2009-2020 Study

  • Report
  • January 2020
  • 156 Pages
  • Japan
From
EUR$4,500USDGBP
Biosimilar Commercial Strategies and Tactics - Product Thumbnail Image

Biosimilar Commercial Strategies and Tactics

  • Report
  • May 2019
  • 67 Pages
  • Global
EUR$2,995USDGBP
Global and China Monoclonal Antibody Industry Report, 2019-2025 - Product Thumbnail Image

Global and China Monoclonal Antibody Industry Report, 2019-2025

  • Report
  • April 2019
  • 180 Pages
  • China, Global
From
EUR$3,000USDGBP
EUR$229USDGBP
EUR$249USDGBP
EUR$299USDGBP
From
EUR$3,957USDGBP
Loading Indicator

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers. Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more